Inflammation as a Therapeutic Target in Atherosclerosis

Research output: Contribution to journalReview article

Abstract

Atherosclerotic coronary artery disease (CAD) results from build-up of cholesterol-rich plaques in the walls of the coronary arteries and is a leading cause of death. Inflammation is central to atherosclerosis. Uncontrolled inflammation makes coronary plaques "unstable" and vulnerable to rupture or erosion, leading to thrombosis and myocardial infarction (MI). As multiple inflamed plaques often co-exist in the coronary system, patients are at risk of repeated atherothrombotic cardiovascular events after MI, with rates of 10-12% at one year and 18-20% at three years. This is largely because current therapies for CAD, such as lipid-lowering statins, do not adequately control plaque inflammation. New anti-atherosclerotic agents are therefore needed, especially those that better target inflammation. The recent positive results for the anti-interleukin-1-beta (IL-1β) monoclonal antibody, Canakinumab, in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) clinical trial has provided a major stimulant to the field. It highlights that not only is inflammation important from a pathogenic and risk prediction perspective in CAD, but that reducing inflammation can be beneficial. The challenge is now to find the best strategies to achieve this in real-world practice. This review outlines the role that inflammation plays in atherosclerosis and provides an update on anti-inflammatory therapies currently being investigated to target atherosclerosis.

LanguageEnglish
JournalJournal of Clinical Medicine
Volume8
Issue number8
DOIs
Publication statusPublished - 26 Jul 2019

Keywords

  • inflammation
  • atherosclerosis
  • C-reactive protein
  • canakinumab
  • methotrexate
  • Colchicine
  • interleukin

Cite this

@article{9551a5070c3c447eaa90491c361c7bfe,
title = "Inflammation as a Therapeutic Target in Atherosclerosis",
abstract = "Atherosclerotic coronary artery disease (CAD) results from build-up of cholesterol-rich plaques in the walls of the coronary arteries and is a leading cause of death. Inflammation is central to atherosclerosis. Uncontrolled inflammation makes coronary plaques {"}unstable{"} and vulnerable to rupture or erosion, leading to thrombosis and myocardial infarction (MI). As multiple inflamed plaques often co-exist in the coronary system, patients are at risk of repeated atherothrombotic cardiovascular events after MI, with rates of 10-12{\%} at one year and 18-20{\%} at three years. This is largely because current therapies for CAD, such as lipid-lowering statins, do not adequately control plaque inflammation. New anti-atherosclerotic agents are therefore needed, especially those that better target inflammation. The recent positive results for the anti-interleukin-1-beta (IL-1β) monoclonal antibody, Canakinumab, in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) clinical trial has provided a major stimulant to the field. It highlights that not only is inflammation important from a pathogenic and risk prediction perspective in CAD, but that reducing inflammation can be beneficial. The challenge is now to find the best strategies to achieve this in real-world practice. This review outlines the role that inflammation plays in atherosclerosis and provides an update on anti-inflammatory therapies currently being investigated to target atherosclerosis.",
keywords = "inflammation, atherosclerosis, C-reactive protein, canakinumab, methotrexate, Colchicine, interleukin",
author = "Nguyen, {Mau T} and Sanuja Fernando and Nisha Schwarz and Tan, {Joanne Tm} and Bursill, {Christina A} and Psaltis, {Peter J}",
year = "2019",
month = "7",
day = "26",
doi = "10.3390/jcm8081109",
language = "English",
volume = "8",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
number = "8",

}

Inflammation as a Therapeutic Target in Atherosclerosis. / Nguyen, Mau T; Fernando, Sanuja; Schwarz, Nisha; Tan, Joanne Tm; Bursill, Christina A; Psaltis, Peter J.

In: Journal of Clinical Medicine, Vol. 8, No. 8, 26.07.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Inflammation as a Therapeutic Target in Atherosclerosis

AU - Nguyen, Mau T

AU - Fernando, Sanuja

AU - Schwarz, Nisha

AU - Tan, Joanne Tm

AU - Bursill, Christina A

AU - Psaltis, Peter J

PY - 2019/7/26

Y1 - 2019/7/26

N2 - Atherosclerotic coronary artery disease (CAD) results from build-up of cholesterol-rich plaques in the walls of the coronary arteries and is a leading cause of death. Inflammation is central to atherosclerosis. Uncontrolled inflammation makes coronary plaques "unstable" and vulnerable to rupture or erosion, leading to thrombosis and myocardial infarction (MI). As multiple inflamed plaques often co-exist in the coronary system, patients are at risk of repeated atherothrombotic cardiovascular events after MI, with rates of 10-12% at one year and 18-20% at three years. This is largely because current therapies for CAD, such as lipid-lowering statins, do not adequately control plaque inflammation. New anti-atherosclerotic agents are therefore needed, especially those that better target inflammation. The recent positive results for the anti-interleukin-1-beta (IL-1β) monoclonal antibody, Canakinumab, in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) clinical trial has provided a major stimulant to the field. It highlights that not only is inflammation important from a pathogenic and risk prediction perspective in CAD, but that reducing inflammation can be beneficial. The challenge is now to find the best strategies to achieve this in real-world practice. This review outlines the role that inflammation plays in atherosclerosis and provides an update on anti-inflammatory therapies currently being investigated to target atherosclerosis.

AB - Atherosclerotic coronary artery disease (CAD) results from build-up of cholesterol-rich plaques in the walls of the coronary arteries and is a leading cause of death. Inflammation is central to atherosclerosis. Uncontrolled inflammation makes coronary plaques "unstable" and vulnerable to rupture or erosion, leading to thrombosis and myocardial infarction (MI). As multiple inflamed plaques often co-exist in the coronary system, patients are at risk of repeated atherothrombotic cardiovascular events after MI, with rates of 10-12% at one year and 18-20% at three years. This is largely because current therapies for CAD, such as lipid-lowering statins, do not adequately control plaque inflammation. New anti-atherosclerotic agents are therefore needed, especially those that better target inflammation. The recent positive results for the anti-interleukin-1-beta (IL-1β) monoclonal antibody, Canakinumab, in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) clinical trial has provided a major stimulant to the field. It highlights that not only is inflammation important from a pathogenic and risk prediction perspective in CAD, but that reducing inflammation can be beneficial. The challenge is now to find the best strategies to achieve this in real-world practice. This review outlines the role that inflammation plays in atherosclerosis and provides an update on anti-inflammatory therapies currently being investigated to target atherosclerosis.

KW - inflammation

KW - atherosclerosis

KW - C-reactive protein

KW - canakinumab

KW - methotrexate

KW - Colchicine

KW - interleukin

U2 - 10.3390/jcm8081109

DO - 10.3390/jcm8081109

M3 - Review article

VL - 8

JO - Journal of Clinical Medicine

T2 - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 8

ER -